文献速递胸部肿瘤

肺癌手术后辅助化疗延迟与生存的关联

Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery.
PubMed 文献 · JAMA Oncol · 2017-01-01

这项回顾性观察研究基于美国国家癌症数据库,纳入2004年1月至2012年12月间完全切除的非小细胞肺癌术后接受多药辅助化疗的患者,评估化疗启动时间与生存的关系。限制性立方样条Cox模型显示术后50天(95%CI 39-56天)启动化疗死亡风险最低;57-127天启动未增加死亡风险(HR 1.037;95%CI 0.972-1.105;P=.27),倾向匹配分析中该间隔化疗较单纯手术死亡风险更低(HR 0.664;95%CI 0.623-0.707;P<.001)。

要点

  • 术后50天(95%CI 39-56天)启动辅助化疗时死亡风险最低。
  • 术后57-127天启动化疗未增加死亡风险(HR 1.037;95%CI 0.972-1.105;P=.27)。
  • 倾向匹配的3976对患者中,较晚启动化疗者死亡风险低于单纯手术者(HR 0.664;95%CI 0.623-0.707;P<.001)。

核心结论

  • 在美國国家癌症数据库中,非小细胞肺癌切除术后7至18周启动辅助化疗仍有效。
  • 非小细胞肺癌手术后恢复缓慢的患者,术后至多4个月启动的延迟辅助化疗仍可能获益。

研究设计与样本

  • 回顾性观察研究,纳入2004年1月至2012年12月间完全切除的非小细胞肺癌术后18至127天接受多药辅助化疗的初治患者。
  • 研究人群限于淋巴结转移、肿瘤4 cm或更大或局部侵犯的患者,来自美国国家癌症数据库。
  • 共纳入12473例患者(中位年龄64岁,四分位距57-70岁),其中I期3073例(25%)、II期5981例(48%)、III期3419例(27%)。
  • 采用限制性立方样条Cox模型评估辅助化疗启动时间与生存的关联。

主要发现

  • 限制性立方样条Cox模型显示术后50天(95%CI 39-56天)启动化疗时死亡风险最低。
  • 在该间隔之后(57-127天,即较晚队列)启动化疗未增加死亡风险(HR 1.037;95%CI 0.972-1.105;P=.27)。
  • 在3976对倾向匹配患者的Cox模型中,较晚间隔接受化疗者死亡风险低于仅接受手术者(HR 0.664;95%CI 0.623-0.707;P<.001)。

临床怎么用

  • 原文结论指出非小细胞肺癌切除术后7至18周启动辅助化疗仍有效。
  • 作者认为手术恢复缓慢的患者术后至多4个月启动的延迟辅助化疗仍可能获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Adjuvant chemotherapy offers a survival benefit to a number of staging scenarios in non-small-cell lung cancer. Variable recovery from lung cancer surgery may delay a patient's ability to tolerate adjuvant chemotherapy, yet the urgency of chemotherapy initiation is unclear. OBJECTIVE: To assess differences in survival according to the time interval between non-small-cell lung cancer resection and the initiation of postoperative chemotherapy to determine the association between adjuvant treatment timing and efficacy. DESIGN, SETTING, AND PARTICIPANTS: This retrospective observational study examined treatment-naive patients with completely resected non-small-cell lung cancer who received postoperative multiagent chemotherapy between 18 and 127 days after resection between January 2004 and December 2012. The study population was limited to patients with lymph node metastases, tumors 4 cm or larger, or local extension. Patients were identified from the National Cancer Database, a hospital-based tumor registry that captures more than 70% of incident lung cancer cases in the United States. The association between time to initiation of adjuvant chemotherapy and survival was evaluated using Cox models with restricted cubic splines. EXPOSURES: Adjuvant chemotherapy administered at different time points after surgery. MAIN OUTCOMES AND MEASURES: Effectiveness of adjuvant chemotherapy according to time to initiation after surgery. RESULTS: A total of 12 473 patients (median [interquartile range] age, 64 [57-70] years) were identified: 3073 patients (25%) with stage I disease; 5981 patients (48%), stage II; and 3419 patients (27%), stage III. A Cox model with restricted cubic splines identified the lowest mortality risk when chemotherapy was started 50 days postoperatively (95% CI, 39-56 days). Initiation of chemotherapy after this interval (57-127 days; ie, the later cohort) did not increase mortality (hazard ratio [HR], 1.037; 95% CI, 0.972-1.105; P = .27). Furthermore, in a Cox model of 3976 propensity-matched pairs, patients who received chemotherapy during the later interval had a lower mortality risk than those treated with surgery only (HR, 0.664; 95% CI, 0.623-0.707; P < .001). CONCLUSIONS AND RELEVANCE: In the National Cancer Database, adjuvant chemotherapy remained efficacious when started 7 to 18 weeks after non-small-cell lung cancer resection. Patients who recover slowly from non-small-cell lung cancer surgery may still benefit from delayed adjuvant chemotherapy started up to 4 months after surgery.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Salazar MC, Rosen JE, Wang Z, et al. Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery. JAMA Oncol. 2017. PMID: 28056112. doi:10.1001/jamaoncol.2016.5829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。